Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Mirum Pharmaceuticals

Nasdaq:MIRM
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MIRM
Nasdaq
$340M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Mirum Pharmaceuticals has significant price volatility in the past 3 months.
MIRM Share Price and Events
7 Day Returns
19.9%
NasdaqGM:MIRM
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-
NasdaqGM:MIRM
0%
US Biotechs
-11.5%
US Market
MIRM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mirum Pharmaceuticals (MIRM) 19.9% -13.9% -47.5% - - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • No trading data on MIRM.
  • No trading data on MIRM.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

MIRM Value

 Is Mirum Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Mirum Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Mirum Pharmaceuticals.

NasdaqGM:MIRM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:MIRM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.203 (1 + (1- 21%) (1.07%))
1.143
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.143 * 5.44%)
7.96%

Discounted Cash Flow Calculation for NasdaqGM:MIRM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Mirum Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:MIRM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.96%)
2020 -67.83 Analyst x2 -62.83
2021 -110.05 Analyst x2 -94.43
2022 -55.11 Analyst x2 -43.80
2023 -39.78 Analyst x2 -29.29
2024 44.10 Analyst x2 30.08
2025 68.03 Est @ 54.24% 42.97
2026 94.21 Est @ 38.49% 55.13
2027 120.08 Est @ 27.46% 65.09
2028 143.80 Est @ 19.75% 72.20
2029 164.42 Est @ 14.34% 76.47
Present value of next 10 years cash flows $111.00
NasdaqGM:MIRM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $164.42 × (1 + 1.74%) ÷ (7.96% – 1.74%)
$2,691.36
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,691.36 ÷ (1 + 7.96%)10
$1,251.75
NasdaqGM:MIRM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $111.00 + $1,251.75
$1,362.75
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,362.75 / 24.97
$54.58
NasdaqGM:MIRM Discount to Share Price
Calculation Result
Value per share (USD) From above. $54.58
Current discount Discount to share price of $13.60
= -1 x ($13.60 - $54.58) / $54.58
75.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Mirum Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $13.6 vs Future cash flow value of $54.58
Current Discount Checks
For Mirum Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Mirum Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Mirum Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mirum Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mirum Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:MIRM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-4.58
NasdaqGM:MIRM Share Price ** NasdaqGM (2020-03-27) in USD $13.6
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mirum Pharmaceuticals.

NasdaqGM:MIRM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MIRM Share Price ÷ EPS (both in USD)

= 13.6 ÷ -4.58

-2.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mirum Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Mirum Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Mirum Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:MIRM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.97x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
34.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mirum Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mirum Pharmaceuticals's assets?
Raw Data
NasdaqGM:MIRM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.77
NasdaqGM:MIRM Share Price * NasdaqGM (2020-03-27) in USD $13.6
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:MIRM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MIRM Share Price ÷ Book Value per Share (both in USD)

= 13.6 ÷ 5.77

2.36x

* Primary Listing of Mirum Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mirum Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Mirum Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Mirum Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MIRM Future Performance

 How is Mirum Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mirum Pharmaceuticals expected to grow at an attractive rate?
  • Mirum Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Mirum Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Mirum Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:MIRM Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:MIRM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 34.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:MIRM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:MIRM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 262 41 99 4
2023-12-31 153 -43 -29 4
2022-12-31 85 -57 -92 4
2021-12-31 15 -100 -107 4
2020-12-31 0 -65 -84 4
2020-03-28
NasdaqGM:MIRM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -39 -53
2019-09-30 -26 -61
2018-12-31 -1 -26

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mirum Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Mirum Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:MIRM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Mirum Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MIRM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.74 3.92 1.56 2.00
2023-12-31 -0.84 -0.63 -1.05 2.00
2022-12-31 -2.94 -2.93 -2.94 2.00
2021-12-31 -3.67 -3.24 -4.09 2.00
2020-12-31 -3.39 -3.06 -3.71 2.00
2020-03-28
NasdaqGM:MIRM Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -4.58
2019-09-30 -9.33
2018-12-31 -28.93

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mirum Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Mirum Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mirum Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MIRM Past Performance

  How has Mirum Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mirum Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mirum Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Mirum Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mirum Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Mirum Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mirum Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MIRM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -52.55 11.75 42.99
2019-09-30 -60.55 8.28 32.10
2018-12-31 -26.02 0.88 3.50

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mirum Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mirum Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mirum Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mirum Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mirum Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MIRM Health

 How is Mirum Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mirum Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mirum Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mirum Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mirum Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.6878158116091E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mirum Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGM:MIRM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 130.35 0.00 116.66
2019-09-30 146.20 0.00 126.26
2018-12-31 42.54 0.00 51.96
  • Mirum Pharmaceuticals's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Mirum Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mirum Pharmaceuticals has sufficient cash runway for 2.9 years based on current free cash flow.
  • Mirum Pharmaceuticals has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 98.9% each year.
X
Financial health checks
We assess Mirum Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mirum Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MIRM Dividends

 What is Mirum Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mirum Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Mirum Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mirum Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mirum Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:MIRM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:MIRM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mirum Pharmaceuticals has not reported any payouts.
  • Unable to verify if Mirum Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mirum Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mirum Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Mirum Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Mirum Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mirum Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mirum Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MIRM Management

 What is the CEO of Mirum Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Peetz
COMPENSATION $5,949,085
AGE 40
TENURE AS CEO 1 years
CEO Bio

Mr. Christopher Peetz, also known as Chris, is a co-Founder of Mirum Pharmaceuticals, Inc., and has been its President since December 2018 and Chief Executive Officer since March 2019. Mr. Peetz serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He joined Frazier in May 2017, is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced business leader in therapeutic development and commercialization. Mr. Peetz was a Founder and Chief Executive Officer of Flashlight Therapeutics, Inc. He is also the President of Mirum Pharmaceuticals. He has been Director of Alpine Immune Sciences, Inc. since April 24, 2018. He served as the Chief Financial Officer and Head of Corporate Development at Tobira Therapeutics, Inc. from March 26, 2014 to December 2016. Mr. Peetz has blend of financial and business acumen. Mr. Peetz joined Tobira from Jennerex, where he served as Vice President of Finance & Corporate Development. Prior to Jennerex, Mr. Peetz held positions of increasing responsibility at Onyx Pharmaceuticals, Inc. (now Amgen), including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles on Nexavar(R), Stivarga(R) and Kyprolis(R). While at Onyx, Mr. Peetz supported public financings of nearly $300 million. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. Mr. Peetz received an MBA from Stanford Graduate School of Business and BSBA from Washington University in St. Louis.

CEO Compensation
  • Chris's compensation has increased whilst company is loss making.
  • Chris's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Mirum Pharmaceuticals management team in years:

1
Average Tenure
48
Average Age
  • The average tenure for the Mirum Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Chris Peetz

TITLE
President
COMPENSATION
$6M
AGE
40
TENURE
1 yrs

Pam Vig

TITLE
Chief Scientific Officer
COMPENSATION
$3M
AGE
48
TENURE
1.3 yrs

Lara Longpre

TITLE
Chief Development Officer
COMPENSATION
$3M
AGE
49
TENURE
1.3 yrs

Ian Clements

TITLE
Chief Financial Officer
AGE
49
TENURE
1 yrs

Ed Tucker

TITLE
Chief Medical Officer
AGE
47
TENURE
0.4 yrs

Thomas Jaecklin

TITLE
Senior Vice President of Clinical Development

Bernard Parker

TITLE
Senior Vice President of Global Commercialization
Board of Directors Tenure

Average tenure and age of the Mirum Pharmaceuticals board of directors in years:

1.3
Average Tenure
52
Average Age
  • The average tenure for the Mirum Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mike Grey

TITLE
Chairman of the Board
COMPENSATION
$6M
AGE
66
TENURE
1 yrs

Chris Peetz

TITLE
President
COMPENSATION
$6M
AGE
40

Ed Mathers

TITLE
Independent Director
COMPENSATION
$21K
AGE
59
TENURE
1.3 yrs

Niall O'Donnell

TITLE
Independent Director
COMPENSATION
$23K
AGE
46
TENURE
1.3 yrs

Laura Brege

TITLE
Independent Director
COMPENSATION
$195K
AGE
61
TENURE
0.7 yrs

Tiba Aynechi

TITLE
Independent Director
AGE
44
TENURE
1.3 yrs

Laurent Fischer

TITLE
Independent Director
COMPENSATION
$450K
AGE
55
TENURE
0.8 yrs

Patrick Heron

TITLE
Independent Director
COMPENSATION
$19K
AGE
49
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Mirum Pharmaceuticals individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
23. Mar 20 Buy Edwin Tucker Individual 19. Mar 20 20. Mar 20 4,500 $11.90 $49,558
18. Sep 19 Buy Laurent Fischer Individual 16. Sep 19 17. Sep 19 2,100 $9.47 $19,716
12. Sep 19 Buy Laura Brege Individual 10. Sep 19 10. Sep 19 10,000 $11.22 $112,200
10. Sep 19 Buy Ian Clements Individual 06. Sep 19 06. Sep 19 4,000 $11.87 $46,039
10. Sep 19 Buy Pamela Vig Individual 06. Sep 19 06. Sep 19 1,612 $11.88 $17,682
10. Sep 19 Buy Christopher Peetz Individual 06. Sep 19 09. Sep 19 9,070 $11.35 $99,938
10. Sep 19 Buy Laurent Fischer Individual 06. Sep 19 10. Sep 19 4,650 $11.30 $49,303
24. Jul 19 Buy Deerfield Management Company, L.P. Company 22. Jul 19 22. Jul 19 332,000 $15.00 $4,980,000
24. Jul 19 Buy New Enterprise Associates, Inc. Company 22. Jul 19 22. Jul 19 450,000 $15.00 $6,750,000
24. Jul 19 Buy Frazier Healthcare Partners Company 22. Jul 19 22. Jul 19 450,000 $15.00 $6,750,000
24. Jul 19 Buy RiverVest Venture Partners, LLC Company 22. Jul 19 22. Jul 19 300,000 $15.00 $4,500,000
23. Jul 19 Buy Novo Holdings A/S Company 22. Jul 19 22. Jul 19 575,000 $15.00 $8,625,000
X
Management checks
We assess Mirum Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mirum Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MIRM News

Simply Wall St News

MIRM Company Info

Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.

Details
Name: Mirum Pharmaceuticals, Inc.
MIRM
Exchange: NasdaqGM
Founded: 2018
$339,550,384
24,966,940
Website: http://mirumpharma.com
Address: Mirum Pharmaceuticals, Inc.
950 Tower Lane,
Suite 1050,
Foster City,
California, 94404,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MIRM Common Stock Nasdaq Global Market US USD 18. Jul 2019
Number of employees
Current staff
Staff numbers
33
Mirum Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:40
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/19
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.